Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00924703 · ClinicalTrials.gov registry record · Phase 2
Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)
A Phase 2 study, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT00924703 is a Phase 2 study that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 68 participants.
The verdict
NCT00924703, a Phase 2 study, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
This study is an extension of previous rAvPAL-PEG studies. Administration of rAvPAL-PEG will be continued to assess whether long-term dosing of rAvPAL-PEG is safe and can maintain reduced blood Phe concentrations in PKU subjects.
Interventions
- DRUG rAvPAL-PEG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2010-01-13 |
| Est. Completion | 2019-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00924703
The ClinicalTrials.gov registry entry for NCT00924703 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rAvPAL-PEG is the first listed.
NCT00924703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00924703 about?
NCT00924703 is a clinical study titled "Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)". This study is an extension of previous rAvPAL-PEG studies. Administration of rAvPAL-PEG will be continued to assess whether long-term dosing of rAvPAL-PEG is safe and can maintain reduced blood Phe concentrations in PKU subjects.
What is the current status of trial NCT00924703?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2010-01-13. Estimated completion is 2019-01-31.
What interventions are being tested in trial NCT00924703?
The interventions under investigation include: rAvPAL-PEG (DRUG).
Who is sponsoring clinical trial NCT00924703?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.